Tarlatamab sustained clinical benefit and safety in previously treated SCLC: DeLLphi-301 phase 2 extended follow-up
Authors
Sands, J.Cho, B. C.
Ahn, M. J.
Reck, M.
Bustamante-Alvarez, J.
Hummel, H. D.
Akamatsu, H.
Johnson, M. L.
Felip, E.
Handzhiev, S.
Korantzis, I.
Izumi, H.
Dingemans, A. M.
Blackhall, Fiona
Owonikoko, T. K.
Wolf, J.
Ramalingam, S. S.
Borghaei, H.
Huang, S.
Jiang, T.
Anderson, E. S.
Martinez, P.
Hamidi, A.
Mukherjee, S.
Paz-Ares, L.
Affiliation
Christie NHS Foundation Trust and University of Manchester, Manchester, UKIssue Date
2024